<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04961619</url>
  </required_header>
  <id_info>
    <org_study_id>CDRB436BTR01</org_study_id>
    <nct_id>NCT04961619</nct_id>
  </id_info>
  <brief_title>Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.</brief_title>
  <acronym>LEAD Melanoma</acronym>
  <official_title>A Real-life Study to Evaluate the Use of Adjuvant Treatment With Dabrafenib and Trametinib in Routine Practice in Patients With Completely Resected High-risk Stage III Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-interventional (observational) cohort prospective real life study with primary and&#xD;
      secondary data collection from patients on adjuvant treatment with dabrafenib + trametinib in&#xD;
      patients with completely resected high-risk stage III (stage IIIA [lymph node &gt; 1mm], IIIB,&#xD;
      IIIC and IIID according to AJCC 8th edition) melanoma in Turkey.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prospective registration of completely resected high-risk stage III melanoma patients&#xD;
      treated with dabrafenib and trametinib in the adjuvant setting will be based on collaboration&#xD;
      with centers of excellence on melanoma patients treatment. Pre-identified centers (up to 12)&#xD;
      considered as the most advanced according to their knowledge and experience, will take part&#xD;
      in the patients recruitment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 20, 2021</start_date>
  <completion_date type="Anticipated">October 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse-free survival (RFS) rate</measure>
    <time_frame>12 months</time_frame>
    <description>RFS is the length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total duration of treatment</measure>
    <time_frame>until end of treatment or permanent treatment discontinuation</time_frame>
    <description>Total duration of treatment defined as median time on adjuvant dabrafenib + trametinib treatment (from start to end of treatment/permanent treatment discontinuation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients on treatment</measure>
    <time_frame>Baseline, up to 12 months</time_frame>
    <description>Collection of number of patients on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of permanent study drug discontinuation</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of permanent study drug discontinuation due to any reason will be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of permanent drug discontinuation due to pyrexia and other AEs</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of permanent drug discontinuation due to pyrexia and other AEs will be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence and severity of Adverse Events (AEs)</measure>
    <time_frame>12 months</time_frame>
    <description>Collection of incidence and severity of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedures of the management of Adverse Events (AEs)</measure>
    <time_frame>12 months</time_frame>
    <description>Collection of procedures of the management of Adverse Events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for treatment discontinuation</measure>
    <time_frame>12 months</time_frame>
    <description>death, relapse, AEs, withdrawal of consent, other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average dose of dabrafenib and trametinib used during the treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Average dose of dabrafenib and trametinib used during the treatment including dose reductions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with dabrafenib and trametinib dose reduction during treatment</measure>
    <time_frame>12 months</time_frame>
    <description>collection of the proportion of patients with dabrafenib and trametinib dose reduction during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for dabrafenib and trametinib dose reduction</measure>
    <time_frame>12 months</time_frame>
    <description>Collection of the reason for dabrafenib and trametinib dose reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time since surgery</measure>
    <time_frame>12 months</time_frame>
    <description>Collection of the time since surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of relapse</measure>
    <time_frame>12 months</time_frame>
    <description>Collection of the type of relapse: local, regional or distant</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>dabrafenib and trametinib</arm_group_label>
    <description>patients on adjuvant treatment with dabrafenib + trametinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabrafenib</intervention_name>
    <description>There is no treatment allocation. Patients administered dabrafenib by prescription that have started before inclusion of the patient into the study will be enrolled.</description>
    <arm_group_label>dabrafenib and trametinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trametinib</intervention_name>
    <description>There is no treatment allocation. Patients administered trametinib by prescription that have started before inclusion of the patient into the study will be enrolled.</description>
    <arm_group_label>dabrafenib and trametinib</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Completely resected high-risk stage III melanoma patients treated with dabrafenib and&#xD;
        trametinib in the adjuvant setting&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with complete surgical resection of histologically confirmed AJCC (8th&#xD;
             edition) clinical stage III (stage IIIA [lymph node &gt; 1mm],, IIIB, IIIC, IIID)&#xD;
             melanoma, in whom a decision for adjuvant treatment with dabrafenib and trametinib has&#xD;
             been made before entering the study;&#xD;
&#xD;
          -  V600E mutation-positive cutaneous melanoma;&#xD;
&#xD;
          -  â‰¥ 18 years of age;&#xD;
&#xD;
          -  Written informed consent signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of basic demographic and staging data.&#xD;
&#xD;
          -  Current active participation in an interventional clinical trial for treatment of&#xD;
             melanoma.&#xD;
&#xD;
          -  Pregnancy or breastfeeding women.&#xD;
&#xD;
          -  Current primary diagnosis of a cancer other than melanoma, that requires systemic or&#xD;
             other treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>BRAF V600E mutation</keyword>
  <keyword>dabrafenib</keyword>
  <keyword>trametinib</keyword>
  <keyword>Turkey</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

